C. Noah Israel, M.D., F.A.C.C.

About Us

Home

Educational Information

Physicians

C. Noah Israel, M.D., F.A.C.C.

Address
115 W. Fifth Street
Tyler, TX 75701

Telephone: (903) 595-2283
Fax: (903) 597-2238

Private Practice

1982-Present: Cardiovascular Associates of East Texas, P.A., Tyler, Texas

Education

Academic Degrees

1968 – 1972, York College of the City University of New York, BA: Biology
1972 – 1976: University Autonoma of Guadalajara, Doctor of Medicine

Post-Doctoral Training

1976 – 1977: Fifth Pathway-Rotating Clinical Clerkship, Nassau County Medical Center, Stony, Brook, New York
1977 – 1980: Internal Medicine Residency, Danbury Hospital, Danbury, Connecticut

Cardiology Fellowship

1980 – 1982: Baystate Medical Center, Springfield, Massachusetts

Board Certification

November 1999: Diplomate Certification Board for Nuclear Cardiology
November 1983: Diplomate American Board of Cardiovascular Disease
September 1981: Diplomate American Board of Internal Medicine
December 2006: International Board of Heart Rhythm Examiners, Formerly NASP Exam #0049

Licensure

October 1995: Nuclear Radiation Certification State of Texas #L04800
August 1982: Texas State Board of Medical Examiners #G2396
April 1980: State of Massachusetts #46614
February 1979: State of Connecticut Department of Health #20533
September 1977: The University of the State of New York #132267

Hospital Appointments

1982 – Present: Staff - Trinity Mother Frances Hospital, Tyler, Texas
1982 – Present: Staff - East Texas Medical Center-Tyler, Tyler, Texas
1990 – Present: Consulting – East Texas Medical Center – Crockett, Texas
1991 – Present: Consultant – East Texas Medical Center – Quitman, Texas
1993 – Present: Consultant – East Texas Medical Center – Athens, Texas
2000 – Present: Consultant – East Texas Medical Center – Carthage, Texas
2001 – Present: Courtesy/Non-Active – Trinity Mother Frances Hospital – Jacksonville, Texas

Administrative Appointments

1996 – 2003: Medical Director Cardiovascular Services, East Texas Medical Center, Tyler, Texas
1983 – 1996: Director of Cardiovascular Rehabilitation, Trinity Mother Frances Hospital, Tyler, Texas
1998 – 2003: Director of Cardiovascular Rehabilitation, East Texas Medical Center, Tyler, Texas
1986 – 1988: Chairman Cardio Pulmonary Section, East Texas Medical Center, Tyler, Texas
1989 – 1994: Adhoc Cardiovascular Task Force Committee, East Texas Medical Center, Tyler, Texas

Professional Societies and Other Memberships

Fellow American College of Cardiology
Fellow American Society of Cardiovascular Interventionists
American College of Phlebology
Society of Cardiac Angiography and Interventions
State Board Member, American Heart Association, Texas Affiliate – Past
Smith County Medical Society
Texas Medical Association
American Medical Association
American Heart Association, Smith County Chapter, Past President
Texas Medical Foundation
American Society of Internal Medicine
American Society of Nuclear Medicine

Research

Primary Investigator - XIENCE™ V: Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study sponsored by Abbott Vascular Inc.
Primary Investigator – RECORD-AF - REgistry on Cardiac rhythm disORDers: an international, observational, prospective survey assessing the control of Atrial Fibrillation”
Primary Investigator – RE-LY - Randomized Evaluation of Long term anticoagulant therapy (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial.
Primary Investigator – ASPEN Study – “AF Suppression Pacing to Prevent First Episode of Atrial Fibrillation in High Risk Patients” – Study.
Primary Investigator – A-HeFT - A Placebo-Controlled Trial of Bidil Added to Standard Therapy In African-American Patients with Heart Failure.
Primary Investigator - GUSTO-Pilot Trial - TX05 - University of Michigan: Global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries.
Primary Investigator - GUSTO - TX05 - University of Michigan: Global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries.
Primary Investigator - GUSTO - TX05 - University of Michigan: Global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries; angiography substudy.
Primary Investigator - GUSTO - TX05 - University of Michigan: Global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries; two year follow up substudy.
Primary Investigator - GUSTO IV AMI (Protocol CO116T31): A Phase III, randomized, open-label trial evaluating the efficacy and safety of. ReoPro™ (ABCIXIMAB) in combination with reduced dose Retavase™/Rapilysin™ (Recombinant Plasminogen Activator, Reteplase, r-PA) for the treatment of acute myocardial infarction.
Principal Investigator – ER-TIMI 19 – A Phase IV, Open-Label Trial of Prehospital Administration of Retavase® for ST elevation MI – the Early Retavase® (ER) – TIMI 19 Trial
Primary Investigator - MK-383 Protocol #008-00; A randomized, double-blind study of MK-383 in patients with unstable angina pectoris concomitantly receiving Heparin Collaborative Clinical Research, Inc.
Primary Investigator - PACT trial (Plasminogen-Activator Angioplasty Compatibility Trial) A randomized, double-blind placebo controlled study assessing clinical efficacy of bolus infusion TPA to placebo in acute MI patients with rescue angioplasty.
Primary Investigator - IMDUR (isosorbide mononitrate) P94-070 Phase IV Patient Acceptability Program. A study comparing the efficacy, safety and ease of use of three FDA-approved formulation; IMDUR, ISDN, and ISMO. The study design assesses if patients with stable angina pectoris benefit – in terms of fewer anginal attacks, increased exercise tolerance, simplicity and convenience of use.
Principal Investigator – OCTAVE - CV137-120 Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril (OCTAVE) A Phase III, Randomized, Double Blind, Active Controlled Comparison of Omapatrilat and Enalapril in Subjects with newly Diagnosed or Established Hypertension
Principal Investigator - VALIANT Trial Phase III (VALsartan In Acute myocardial iNfarcTion): A multinational, multicenter, double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with Valsartan, Captopril and their combination in high risk patients after myocardial infarction.
Principal Investigator – EPHESUS – IE-99-02-035, Clinical protocol for a double blind, randomized, placebo-controlled trial to evaluating the safety and efficacy of eplerenone in patients with heart failure following acute myocardial infarction.
Investigator - ULTRA study- Ventricular Automatic Capture assessment Study.
Investigator – TRENDS- A prospective, non-randomized, multi-center trial in subjects implanted with a commercially available Medtronic implantable pulse generator (IPG), implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) device. The primary purpose of the trial is to determine if the device trending data are indicators of clinical outcomes in subjects with atrial tachyarrhythmias.
Investigator- MASTER-- Microvolt T Wave AlternanS TEsting for Risk Stratification of Post MI Patients.
Investigator – AWARE - Analysis of a New AT/AF Detection Algorithm in Patients with Atrial Arrhythmias.
Investigator – FiB07 – A randomized, double-blind study comparing the patency rate and safety of two different preparations of Intravenous Eminase (BRL 26921) in patients with acute myocardial infarction.
Investigator – The rapid administration of alteplase (rt-Pa) myocardial infarction (RAAMi) Trial: Increased efficiency of 100 mg of rt-PA with modified dosing.
Investigator – A multi-center, prospective, randomized, placebo-controlled trial of Activase and Heparin in patients with unstable angina (UNSA)
Investigator – An Anglo-Scandinavian North American multi-center trial of Alteplase (rt-PA) therapy in patients who present with acute myocardial infarction six to twenty-four hours following onset of symptoms. (LATE)- Late Assessment of Thrombolytic Efficacy.
Investigator – ISIS-3 – The third international study of infarct survival.
Investigator – Timi-IIIB – Thrombolysis in myocardial ischemia and unstable angina study. Study of the effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q wave myocardial infarction.
Co-Investigator - PLATO Study - A Randomized, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS).
Co-Investigator – ENDEAVOR IV – A Randomized, Controlled Trial of the Medtronic Endeavor Drug Eluting Coronary Stent System versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions.
Co-Investigator – VISION 305 Study - “Vasodilator Induced Stress In Concordance with Adenosine” A multicenter, risk-stratified, randomized, double-blind, double-dummy study drug administration, active-controlled, complete two-arm crossover study with a reference third arm.
Co-Investigator - APEX-AMI Study - “A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of Pexelizumab in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.” (Assessment of PEXelizumab in Acute Myocardial Infarction)-APEX-AMI.
Co-Investigator – TIMI38/TRITON – A Comparison of CS-747 and Clopidrogrel in Acute Coronary Syndrome Patients who are to Undergo Percutaneous Coronary Intervention; a Phase III, multicenter, randomized, parallel-group, double-dummy, active controlled trial in patients with acute coronary syndrome (ACS), who are to undergo percutaneous coronary intervention (PCI).
Co-Investigator - AMIHOT II – A prospective, Multi-center, randomized study of Aqueous Oxygen Therapy for 90 minutes in Anterior Acute MI patients with successful PCI/stenting presenting within 6 hours from time of symptom onset until time of reperfusion.
Co-Investigator - ACCOMPLISH- A prospective, multicenter, double-blind, randomized, active-controlled trial to compare the effects of Lotrel (amlodipine/benazepril to benazepril and hydrochlorothiazide combined on the reduction of cardiovascular morbidity and mortality in patients with high risk hypertension.
Co-Investigator - Extra Point. Protocol # S1710202. Cardiovascular Safety Study of Nicotine Transdermal System.
Co-Investigator - ACUITY Trial- A randomized comparison of Angiomax (bivalirudin) versus Lovenox/Clexane (enoxaparin) in patients undergoing early invasive management for acute coronary syndrome without ST- segment elevation.
Co-Investigator - TMR012-A. A Single-Blind Randomized Study of the Safety and Effectiveness of Percutaneous Transluminal Myocardial Revascularization (PTMR) Performed with the Eclipse Holmium Laser as an Adjunct to Percutaneous Coronary Intervention.
Co-Investigator - Coumadin, Aspirin and Reinfarction Study; "CARS" DuP 647-003 A randomized, double-blind study to compare the efficacy and safety of fixed low doses of Coumadin plus aspirin to aspirin alone in the prevention of reinfarction, cardiovascular death, and stroke in post-myocardial infarction patients.
Co-Investigator - Coumadin, Aspirin and Reinfarction EKG Substudy; "CARS" DuP 647-003 A randomized, double-blind study to compare the efficacy and safety of fixed low doses of Coumadin plus aspirin to aspirin alone in the prevention of reinfarction, cardiovascular death, and stroke in post-myocardial infarction patients.
Co-Investigator – NRMI – National Registry for Myocardial Infarction.
Co-Investigator - PRAISE 2 - (Prospective Randomized Amlodipine Survival Evaluation - 2) Phase III Protocol NO. 053-185: A randomized, double-blind, dose-titration, parallel group, placebo-controlled study to evaluate the effect of Amlodipine on survival in patients with congestive heart failure.
Co-Investigator - BioSlide Catheter SCIMED
Co-Investigator - Paragon B Trial: A randomized, double-blind, placebo-controlled study of Lamifiban (RO44-9883) in patients with unstable angina/non-Q wave myocardial infarction.
Co-Investigator - AMISTAD II Trial (Phase III): A randomized, double-blind, placebo-controlled, multicenter trial to evaluate the efficacy and safety of Adenosine (Pallacor, Adenosine Injection) as an adjunct to reperfusion therapy (Thrombolysis or Mechanical Reperfusion) in the treatment of acute anterolateral myocardial infarction.
Co-Investigator – VALIANT REGISTRY SUBSTUDY : VALIANT Trial Phase III (VALsartan In Acute myocardial iNfarcTion): A multinational, multicenter, double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with Valsartan, Captopril and their combination in high risk patients after myocardial infarction.
Co-Investigator - Niaspan Trial #MA-97-0101 Phase IV: an open-label, community-based clinical practice study of Niaspan in patients with hyperlipidemia.
Co-Investigator - CardioGenesis Transmyocardial Revascularization (TMR) System: To evaluate the safety and efficacy of the CardioGenesis TMR System when used for TMR performed as an adjunct to CABG in patients with angina resulting from coronary artery disease which is only partially treatable by CABG.
Co-Investigator - ATLAS Trial (Aspirin TicLid vs Anticoagulation for Stents) - George Washington University, Cardiovascular Research Institute.
Co-Investigator - DESTINI (Doppler Endpoint Stenting International Investigation): A multicenter randomized prospective evaluation of clinical outcome comparing primary stenting and a new practice pattern of optimal balloon angioplasty guided by quantitative angiography and intracoronary Doppler.
Co-Investigator – MICCAT ( MICardis Community Access Trial) An Phase IV – Open label evaluation of the effectiveness of Micardisâ ( telmisartan) on blood pressure control and quality of life in patients with essential hypertension.
Co-Investigator – GUSTO IV ACS – A phase III, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ReoPro™, given as a bolus followed by a 24- or 48-hour infusion, for the treatment of acute coronary syndrome without ST-segment elevation.
Co-Investigator – STEP AMI – An Open Study, with Blinded Endpoint Assessment, to Assess the Safety, Tolerability and the Effect on Coronary Artery Patency of Intravenous AR-C69931MX as both Monotherapy and Adjunct to Activase in Patients with ST-elevation Myocardial Infarction.
Co-Investigator – REPLACE – TMC-BIV-00-01, Randomized Evaluation in Percutaneous Coronary Intervention Linking Angiomax to Reduced Clinical Events.
Co-Investigator - REPLACE II - A Randomized Evaluation in PCI Linking
Angiomax to Reduced Clinical Events, Part 2: REPLACE-2 (TMC-BIV-01-03)
Co-Investigator – SYNERGY - A Prospective, Randomized, Open-Label, Multicenter Study in Patients Presenting with Acute Coronary Syndromes (ACS).
Aventix Pharmaceuticals Protocol Number ENO.GMA.301. IND# 31532
Co-Investigator – A Double-Blind Comparison Of The Incidence Of Hypotension With Two Formulations Of Intravenous Amiodarone: CordaroneÒ I.V. vs Amiodarone Aqueous I.V. Injection - Protocol No. 058K1-312-US
Co-Investigator – CRISP - A single Arm, Open label Study of Cervastatin (Baycol®) in Community based Patients with Hypercholesterolemia at risk for Cardiovascular Disease and patients with Cardiovascular Disease. To Monitor inflammatory markers
Co-Investigator-INSPIRE :A Randomized, Prospective Multicenter Trial Evaluating The Role Of Adenosine Tc99m Sestamibi SinglepPhoton Emission Computed Tomography For Assessing Risk And Therapeutic Outcomes In Survivors Of Acute Myocardial Infarction.
Co-Investigator – Otsuka Protocol 21-98-214-01 CASTLE “ A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Arm, Study to Asses The Long-Term Effects of Pletal® (Cilostazol) Versus Placebo Administered Orally to Patients with Intermittent Claudication Secondary to Peripheral Arterial Disease”.
Co-Investigator – AMIHOT – TherOx Aqueous Oxygen System – Acute Myocardial Infarction with Hyperoxemic Therapy “AMIHOT” Phase II clinical trial. A Randomized, Controlled, Multicenter Trial of Aqueous Oxygen Infusion for 90 Minutes Post-Primary PTCA/Stent Intervention in Acute Myocardial Infarction Patients.
Co-Investigator – AGENT 3 - A Multicenter, Randomized, Double-blind, PlaceboControlled Study to Evaluate the Efficacy and Safety of Ad5FGF-4 in Patients with Stable Angina
Co-Investigator – Extra Point. Protocol # S1710202. Cardiovascular
Safety Study of Nicotine Transdermal System

Publications

Jonathan S. Reiner, Conor F. Lundergan, Noah Israel, George Pilcher, Steven Rohrbeck, Mark Thompson, Allan M. Ross for the GUSTO –1 investigators George Washington Univ., Wash., DC: Ventriculographic Evolution in MI Patients with Early Timi 2 Flow;
Improving Flow Results in Improving Left Ventricular Function.
Circulation Vol 92 No 8 Oct. 15, 1995 (ABSTRACT)
Jonathan S. Reiner, MD; Conor F. Lundergan, MD; Anthony Fung, MD; Karin Coyne, R.N. MPH; Shyuan Cho, MS; Noah Israel, MD; John Kazmierski, MD; George Pilcher, MD; James Smith, MD; Steven Rohrbeck, MD; Mark Thompson, MD; Frans Van de Werf, MD; Allan M. Ross, MD; for the Gusto-1 Angiographic Investigators. Evolution of Early TIMI 2 Flow After Thrombolysis for Acute Myocardial Infarction
Circulation Vol 94, No 10 Nov. 15, 1996